Gerd R Burmester

63.6k citations

596 papers · 28.3k indexed · 10 hit papers · h-index 87

Rheumatology top 0.01%
- Rheumatoid Arthritis Research and Therapies 320
- Systemic Lupus Erythematosus Research 139
- Spondyloarthritis Studies and Treatments 48
Hematology top 0.05%
- Autoimmune and Inflammatory Disorders Research 136
Immunology top 0.1%
- T-cell and B-cell Immunology 45
Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research 103
Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 51
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 99

Co-authors: Thomas Dörner Janet Pope Eugen Feist Thomas Häupl Iain B. McInnes Michael Sittinger Robert Winchester Ronald van Vollenhoven
Cited by: Rheumatology Hematology Immunology
Partner nations: Germany United States United Kingdom

In The Last Decade

Gerd R Burmester

575 papers receiving 27.4k citations

Hit Papers

10 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2023 Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
2020 The etiology of rheumatoid arthritis
2020 Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
2020 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
2018 Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
2018 Rheumatoid arthritis
2017 Novel treatment strategies in rheumatoid arthritis
2013 Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
2012 Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
2005 Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

Peers

Countries citing papers authored by Gerd R Burmester

Since Specialization

Citations

This map shows the geographic impact of Gerd R Burmester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerd R Burmester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerd R Burmester more than expected).

Fields of papers citing papers by Gerd R Burmester

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerd R Burmester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerd R Burmester. The network helps show where Gerd R Burmester may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gerd R Burmester, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerd R Burmester Line = papers co-authored together Gerd R Burmester links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years Christina Charles‐Schoeman,Jon T. Giles,Nancy E. Lane,Ernest Choy,Daniel E. Fürst,Jiří Vencovský,Anthony G. Wilson,Gerd R Burmester,Derek Coombs,S. Penn,Nasser Khan,Jillian B. Yee,Kassim Rahawi,Iain B. McInnes	2024	5
2	Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47 Josef S Smolen,Jakub Trefler,Artur Racewicz,Janusz Jaworski,Agnieszka Zielińska,Marek Krogulec,Sławomir Jeka,Rafał Wojciechowski,Katarzyna Kolossa,Anna Dudek,Magdalena Krajewska–Włodarczyk,Paweł Hrycaj,Piotr Adrian Klimiuk,Gerd R Burmester,Sung Hyun Kim,Yunju Bae,Go Eun Yang,Yeonsoon Jung,JiWoo Hong,Edward Keystone	2024	3
3	Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study Miwa Haranaka,Takashi Eto,Takanori Tanaka,Rie Yazawa,Gerd R Burmester,Edward Keystone,Sung Hyun Kim,Yun Ju Bae,JeeHye Suh,Grace Yang,YunAh Kim,J. Lee,Josef S Smolen	2024	2
4	Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT) Gerd R Burmester,Filip Van den Bosch,John Tesser,Anna Shmagel,Yanxi Liu,Nasser Khan,Heidi S. Camp,Alan Kivitz	2024	3
5	Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests Elisa Habermann,Leonie Maria Frommert,Khetam Ghannam,L.N. My,Lutz Gieselmann,Pinkus Tober‐Lau,Jens Klotsche,Amanthi Nadira Arumahandi de Silva,Alexander ten Hagen,Jan Zernicke,Florian Kurth,Leif Erik Sander,Florian Klein,Gerd R Burmester,Robert Biesen,Fredrik N. Albach	2023	1
6	Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients Rieke Alten,Gerd R Burmester,Marco Matucci‐Cerinic,Jean‐Hugues Salmon,Andrew J.K. Östör,Khai Jing Ng,Jens Gerwien,Liliana Zaremba-Pechmann,Alan Brnabic,Bruno Fautrel	2023	11
7	OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions Maya H Buch,Bernard Combe,José A. Gómez‐Puerta,Roberto Caporali,Jacques‐Eric Gottenberg,Paul Van Hoek,Vijay Rajendran,Pieter-Jan Stiers,Katrien Van Beneden,Daniel Aletaha,Gerd R Burmester,René Westhovens,Yoshiya Tanaka	2023	1
8	Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review Eric L. Matteson,Marco Matucci‐Cerinic,Michael Kreuter,Gerd R Burmester,Philippe Dieudé,Paul Emery,Yannick Allanore,Janet Pope,Dinesh Khanna	2023	6
9	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies Manuel Graf,Anne Sae Lim von Stuckrad,Akinori Uruha,Jens Klotsche,Lydia Zorn-Pauly,Nadine Unterwalder,Thomas Buttgereit,Martin Krusche,Christian Meisel,Gerd R Burmester,Falk Hiepe,Robert Biesen,Tilmann Kallinich,Werner Stenzel,Udo Schneider,Thomas Rose	2022	25
10	Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA) Michaela Koehm,Ann Christina Foldenauer,Tanja Roßmanith,Rieke Alten,Martin Aringer,Marina Backhaus,Gerd R Burmester,Eugen Feist,Herbert Kellner,Klaus Krueger,Ulf Müller‐Ladner,Andrea Rubbert‐Roth,Hans‐Peter Tony,Siegfried Wassenberg,Harald Burkhardt,Frank Behrens	2022	1
11	Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease Leonie Maria Frommert,Amanthi Nadira Arumahandi de Silva,Jan Zernicke,Veronika Scholz,T. Braun,Lara M. Jeworowski,Tatjana Schwarz,Pinkus Tober‐Lau,Alexander ten Hagen,Elisa Habermann,Florian Kurth,Leif Erik Sander,Victor M. Corman,Gerd R Burmester,Robert Biesen,Fredrik N. Albach,Jens Klotsche	2022	15
12	Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus Lydia Zorn-Pauly,Anne Sae Lim von Stuckrad,Jens Klotsche,Thomas Rose,Tilmann Kallinich,Philipp Enghard,Lennard Ostendorf,Marie E. Burns,Thomas Doerner,Christian Meisel,Udo Schneider,Nadine Unterwalder,Gerd R Burmester,Falk Hiepe,Tobias Alexander,Robert Biesen	2021	10
13	Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program Philip G. Conaghan,Eduardo Mysler,Yoshiya Tanaka,Barbara Da Silva‐Tillmann,Tim Shaw,John Liu,Ryan Ferguson,Jeffrey Enejosa,Stanley Cohen,Peter Nash,William F. C. Rigby,Gerd R Burmester	2021	33
14	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Robert Landewé,Pedro Machado,Féline P B Kroon,Hans Bijlsma,Gerd R Burmester,Loreto Carmona,Bernard Combe,Massimo Galli,Laure Gossec,Annamaria Iagnocco,John D. Isaacs,Xavier Mariette,Iain B. McInnes,Ulf Müeller-Ladner,Peter Openshaw,Josef S Smolen,Tanja Stamm,Dieter Wiek,Hendrik Schulze‐Koops	2020	153
15	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey Rosaria Talarico,Diana Marinello,Stefano Bombardieri,Gerd R Burmester,João Eurico Fonseca,Charissa Frank,Ilaria Galetti,É. Hachulla,Frédéric Houssiau,Ulf Müeller-Ladner,Matthias Schneider,Vanessa Smith,Giuseppe Turchetti,Jacob M. van Laar,Ana Vieira,Maurizio Cutolo,Marta Mosca	2020	8
16	Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis Jürgen Braun,Xenofon Baraliakos,Uta Kiltz,Klaus Krüger,Gerd R Burmester,Siegfried Wassenberg,Matthias H. Thomas	2019	2
17	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases Aurélie Najm,Elena Nikiphorou,Marie Kostine,Christophe Richez,John D Pauling,Axel Finckh,Valentin Ritschl,Yeliz Prior,Petra Balážová,Simon Stones,Zoltán Szekanecz,Annamaria Iagnocco,Sofía Ramiro,Francisca Sivera,Maxime Dougados,Loreto Carmona,Gerd R Burmester,Dieter Wiek,Laure Gossec,Francis Bérenbaum	2019	67
18	Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody Gerd R Burmester,Iain B. McInnes,Joel M. Kremer,Pedro C. Miranda,Jiří Vencovský,A. Godwood,M. Albulescu,M. Alex Michaels,Xiang Guo,D. Close,Michael E. Weinblatt	2018	62
19	A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis Michael E. Weinblatt,Iain B. McInnes,Joel M. Kremer,Pedro C. Miranda,Jiří Vencovský,Xiang Guo,Wendy I. White,Patricia C. Ryan,A. Godwood,M. Albulescu,D. Close,Gerd R Burmester	2017	72
20	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study Paul Emery,Clifton O. Bingham,Gerd R Burmester,Vivian P. Bykerk,Daniel E. Furst,Xavier Mariette,Désirée van der Heijde,Ronald van Vollenhoven,Catherine Arendt,Irina Mountian,O. Purcaru,Daljit Tatla,Michael E. Weinblatt,B. VanLunen	2016	72

About Gerd R Burmester

Gerd R Burmester is a scholar working on Rheumatology, Hematology and Genetics, having authored 596 papers that have together received 28.3k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (320 papers), Systemic Lupus Erythematosus Research (139 papers), Autoimmune and Inflammatory Disorders Research (136 papers), Chronic Lymphocytic Leukemia Research (103 papers), Monoclonal and Polyclonal Antibodies Research (99 papers), Lymphoma Diagnosis and Treatment (51 papers), Spondyloarthritis Studies and Treatments (48 papers) and T-cell and B-cell Immunology (45 papers). The work is most often cited by research in Rheumatology (15.6k citations), Hematology (5.3k citations) and Immunology (8.8k citations). Gerd R Burmester has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Thomas Dörner, Janet Pope, Eugen Feist, Thomas Häupl, Iain B. McInnes, Michael Sittinger, Robert Winchester, Ronald van Vollenhoven, Vibeke Strand and Paul Emery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact